Literature DB >> 19834056

Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.

Susan Wilson1, Saadat Hashamiyan, Lorne Clarke, Paul Saftig, John Mort, Valeria M Dejica, Dieter Brömme.   

Abstract

Mucopolysaccharidoses are a group of lysosomal storage diseases characterized by the build-up of glycosaminoglycans (GAGs) and severe skeletal abnormalities. As GAGs can regulate the collagenolytic activity of the major osteoclastic protease cathepsin K, we investigated the presence and activity of cathepsin K and its co-localization with GAGs in mucopolysaccharidosis (MPS) type I bone. The most dramatic difference between MPS I and wild-type mice was an increase in the amount of cartilage in the growth plates in MPS I bones. Though the number of cathepsin K-expressing osteoclasts was increased in MPS I mice, these mice revealed a significant reduction in cathepsin K-mediated cartilage degradation. As excess heparan and dermatan sulfates inhibit type II collagen degradation by cathepsin K and the spatial overlap between cathepsin K and heparan sulfate strongly increased in MPS I mice, the build up of subepiphyseal cartilage is speculated to be a direct consequence of cathepsin K inhibition by MPS I-associated GAGs. Moreover, isolated MPS I and Ctsk(-/-) osteoclasts displayed fewer actin rings and formed fewer resorption pits on dentine disks, as compared with wild-type cells. These results suggest that the accumulation of GAGs in murine MPS I bone has an inhibitory effect on cathepsin K activity, resulting in impaired osteoclast activity and decreased cartilage resorption, which may contribute to the bone pathology seen in MPS diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834056      PMCID: PMC2774069          DOI: 10.2353/ajpath.2009.090211

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro.

Authors:  P T Lakkakorpi; H K Väänänen
Journal:  J Bone Miner Res       Date:  1991-08       Impact factor: 6.741

2.  Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.

Authors:  R J Riese; P R Wolf; D Brömme; L R Natkin; J A Villadangos; H L Ploegh; H A Chapman
Journal:  Immunity       Date:  1996-04       Impact factor: 31.745

3.  Vinyl sulfones as mechanism-based cysteine protease inhibitors.

Authors:  J T Palmer; D Rasnick; J L Klaus; D Brömme
Journal:  J Med Chem       Date:  1995-08-18       Impact factor: 7.446

4.  Immunohistochemical localization of heparan sulfate proteoglycan in rat tibiae.

Authors:  H Nakamura; H Ozawa
Journal:  J Bone Miner Res       Date:  1994-08       Impact factor: 6.741

5.  Hepatic storage of glycosaminoglycans in feline and canine models of mucopolysaccharidoses I, VI, and VII.

Authors:  M E Haskins; E J Otis; J E Hayden; P F Jezyk; L Stramm
Journal:  Vet Pathol       Date:  1992-03       Impact factor: 2.221

6.  Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts.

Authors:  Kazuhisa Nakano; Yosuke Okada; Kazuyoshi Saito; Yoshiya Tanaka
Journal:  Arthritis Rheum       Date:  2004-08

7.  Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.

Authors:  F H Drake; R A Dodds; I E James; J R Connor; C Debouck; S Richardson; E Lee-Rykaczewski; L Coleman; D Rieman; R Barthlow; G Hastings; M Gowen
Journal:  J Biol Chem       Date:  1996-05-24       Impact factor: 5.157

8.  Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution.

Authors:  D Brömme; K Okamoto
Journal:  Biol Chem Hoppe Seyler       Date:  1995-06

9.  Growth plate pathology in feline mucopolysaccharidosis VI.

Authors:  S Abreu; J Hayden; P Berthold; I M Shapiro; S Decker; D Patterson; M Haskins
Journal:  Calcif Tissue Int       Date:  1995-09       Impact factor: 4.333

10.  The pathology of the feline model of mucopolysaccharidosis I.

Authors:  M E Haskins; G D Aguirre; P F Jezyk; R J Desnick; D F Patterson
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

View more
  41 in total

1.  Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).

Authors:  Jakub Tolar; In-Hyun Park; Lily Xia; Chris J Lees; Brandon Peacock; Beau Webber; Ron T McElmurry; Cindy R Eide; Paul J Orchard; Michael Kyba; Mark J Osborn; Troy C Lund; John E Wagner; George Q Daley; Bruce R Blazar
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

2.  Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.

Authors:  Susan Wilson; Dieter Brömme
Journal:  J Pediatr Rehabil Med       Date:  2010

3.  Prevalence and development of orthopaedic symptoms in the dutch hurler patient population after haematopoietic stem cell transplantation.

Authors:  F J Stoop; M C Kruyt; M H van der Linden; R J B Sakkers; P M van Hasselt; R M C Castelein
Journal:  JIMD Rep       Date:  2012-09-19

4.  Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.

Authors:  Tamara Alliston
Journal:  J Pediatr Rehabil Med       Date:  2010

Review 5.  Brain and spinal MR imaging findings in mucopolysaccharidoses: a review.

Authors:  D I Zafeiriou; S P Batzios
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

6.  Hurler syndrome: orofacial, dental, and skeletal findings of a case.

Authors:  Arpita Rai Thakur; Venkatesh G Naikmasur; Atul Sattur
Journal:  Skeletal Radiol       Date:  2014-08-20       Impact factor: 2.199

7.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

Review 8.  Mucopolysaccharidoses: overview of neuroimaging manifestations.

Authors:  Manal Nicolas-Jilwan; Moeenaldeen AlSayed
Journal:  Pediatr Radiol       Date:  2018-05-11

9.  Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.

Authors:  David A Stevenson; Kyle Rudser; Alicia Kunin-Batson; Ellen B Fung; David Viskochil; Elsa Shapiro; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

10.  Collagenolytic activities of the major secreted cathepsin L peptidases involved in the virulence of the helminth pathogen, Fasciola hepatica.

Authors:  Mark W Robinson; Ileana Corvo; Peter M Jones; Anthony M George; Matthew P Padula; Joyce To; Martin Cancela; Gabriel Rinaldi; Jose F Tort; Leda Roche; John P Dalton
Journal:  PLoS Negl Trop Dis       Date:  2011-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.